Abstract
A 24-week, randomized, controlled trial of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch in patients with severe Alzheimer's disease: Analysis of neuropsychiatric inventory items
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.